home / stock / adma / adma news


ADMA News and Press, ADMA Biologics Inc From 08/11/21

Stock Information

Company Name: ADMA Biologics Inc
Stock Symbol: ADMA
Market: NASDAQ
Website: admabiologics.com

Menu

ADMA ADMA Quote ADMA Short ADMA News ADMA Articles ADMA Message Board
Get ADMA Alerts

News, Short Squeeze, Breakout and More Instantly...

ADMA - ADMA Biologics Reports Record Second Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments

Achieved Record Total Revenues of $17.8 Million in Second Quarter 2021, a 129% Increase Over Second Quarter 2020 Narrowed Gross and Net Losses Year-over-Year ADMA Now Anticipates Exiting 2021 Approaching an Annualized Revenue Run Rate of Approximately $100 Million or Mor...

ADMA - ADMA Biologics Advances Expansion Plans and Opens New Plasma Collection Center in Conyers, GA; ADMA Implements Haemonetics' Persona Technology for NexSys Plasma Collection System

RAMSEY, N.J. and BOCA RATON, Fla. and CONYERS, Ga., Aug. 10, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, annou...

ADMA - ADMA Biologics Announces Commercial Availability of Expanded Vial Size Offerings for BIVIGAM® and NABI-HB®

ADMA Expands Commercial IG Product Offering with Additional BIVIGAM and NABI-HB Vial Sizes BIVIGAM 100 mL Vial and NABI-HB 1 mL Vial Now Commercially Available to U.S. Healthcare Providers RAMSEY, N.J. and BOCA RATON, Fla., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, I...

ADMA - ADMA Biologics to Report Second Quarter 2021 Financial Results on August 11, 2021

RAMSEY, N.J. and BOCA RATON, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived bi...

ADMA - ADMA Biologics Announces Successful Completion of FDA Pre-Approval Manufacturing Facility Inspection

Approval for VanRx Fill-Finish Machine Expected in the Second Half of 2021 All Supply Chain Robustness Initiatives Remain on Schedule RAMSEY, N.J. and BOCA RATON, Fla., July 20, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-...

ADMA - Shares of ADMA Biologics Inc (ADMA) Fall Below Previous 52-Week Low

Shares of ADMA Biologics Inc (NASDAQ:ADMA) traded today at $1.39, breaking its 52-week low. Approximately 315,000 shares have changed hands today, as compared to an average 30-day volume of 2.4 million shares. ADMA Biologics Inc has overhead space with shares priced $1.44, or 22.3% below...

ADMA - ADMA Biologics price target lowered at H.C. Wainwright citing revenue outlook

alexsl/iStock via Getty Images ADMA Biologics (ADMA) has extended its five-day long losing streak for the sixth trading session while H.C. Wainwright cut its price target to $7.00 from $10.00 per share, implying a premium of ~363.6% to the close. Maintaining the buy rating, the analyst Raghur...

ADMA - Bionano Genomics to join Russel 3000 Index, while AcelRx Pharmaceuticals to see deletion among healthcare stocks

At the conclusion of the 2021 Russell indexes annual reconstitution following notable healthcare stocks will join the Russell 3000 Index, effective June 28 after the U.S. market opens.Bionano Genomics (BNGO), Asensus Surgical (ASXC), Ocugen (OCGN), Senseonics Holdings (SEN...

ADMA - ADMA Biologics to Participate in the Raymond James Human Health Innovation Virtual Conference

RAMSEY, N.J. and BOCA RATON, Fla., June 14, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced...

ADMA - ADMA Biologics to Participate in the Jefferies Virtual Healthcare Conference

RAMSEY, N.J. and BOCA RATON, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced ...

Previous 10 Next 10